About this trial
Women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life, even if they are otherwise healthy. Importantly, women who had preeclampsia have an exaggerated vascular responsiveness to hypertensive stimuli, such as high-salt intake, compared to women who had a healthy pregnancy. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during the preeclamptic pregnancy and persists postpartum, despite the remission of clinical symptoms. While the association between a history of preeclampsia and vascular dysfunction leading to elevated CVD risk is well known, the mechanisms underlying this dysfunction remains unclear.
The purpose of this study is to examine the role of vascular mineralocorticoid receptor, the terminal receptor in the angiotensin system that contributes to blood pressure regulation, in mediating exaggerated microvascular endothelial dysfunction before and after a high-salt stimulus. This will help us better understand the mechanisms of microvascular dysfunction these women, and how inhibition of these receptors may improve microvascular function.
In this study, we use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) we examine the blood vessels in a nickel-sized area of the skin.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
women who had preeclampsia and women who did not have preeclampsia
12 weeks to 5 years postpartum
18-45 years old
Disqualifiers
history of hypertension or metabolic disease before pregnancy
history of gestational diabetes
history of gestational hypertension without preeclampsia
skin diseases
Trial design
Single group
Treatments tested in this trial
Eplerenone
DrugLocal heating: eplerenone is locally and acutely delivered to the cutaneous microvasculature during local heating of the skin to assess endothelium-dependent dilation, L-NAME is added to assess nitric oxide-dependent dilation during this response.
Treatment groups
Trial outcomes
Primary outcomes
Change in microvascular endothelial function following local eplerenone treatment compared to placebo treatment measured by laser-Doppler flowmetry
Cutaneous vascular vasodilator response (cutaneous conductance; %max) to local heating of the skin; intradermal microdialysis for the local delivery of eplerenone compared to control (Ringer's solution), followed by L-NAME infusion to quantify NO-dependent response
Changes in 24-hour urine sodium
The investigators will measure urine sodium to ensure differences in salt-take between low- and high-salt.
Secondary outcomes
Changes in circulating aldosterone concentrations
The investigators will collect blood at the start of each experiment to determine differences in aldosterone concentrations between low- and high-salt.
Changes in circulating angiotensin II concentrations
The investigators will collect blood at the start of each experiment to determine differences in circulating angiotensin II concentrations between low- and high-salt.
Changes in ambulatory blood pressure
The investigators will measure ambulatory blood pressure, assessed as mean arterial pressure calculated from measured systolic and diastolic pressures, responses to low- and high-salt.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Anna Stanhewicz, PhD
Lead sponsor
University of Iowa
Sponsor institution